Abbott products

Abbott's mechanical heart valves offer a reliable solution for patients requiring aortic and mitral valve replacements. Featuring a bileaflet design, these valves prioritize low thrombogenicity to ensure excellent patient outcomes. The pivot guard design provides significant benefits during and after implantation. With specific models like the Regent™ and Masters Series, these valves accommodate a broad range of patient needs, including pediatric cases with the world's smallest 15 mm valve. Known for their low complication rates, these devices are suited to deliver optimal hemodynamic performance, reducing shear stress and thromboembolic risks. The availability of various cuff options allows for tailored implantability, and the expanded product sizes enable precise fittings. This technology addresses both symptomatic aortic and mitral valve issues, offering essential options for high-risk groups and long-term durability for everyday patients.

The Epic™ Max Aortic Stented Tissue Valve represents the latest advancement in aortic valve replacement technology, engineered to optimize clinical outcomes and enhance lifetime patient management. It features porcine leaflets for natural leaflet functionality, minimizing calcification and reducing the risk of re-intervention-related stroke. The valve is designed with a large stent internal diameter, facilitating a wider range of valve-in-valve procedures, especially in conjunction with Transcatheter Aortic Valve Implantation (TAVI) prostheses. A unique pericardial shield and low aortic protrusion further reduce the risk of coronary obstruction. Safety and effectiveness for valve-in-valve procedures have not yet been fully established, highlighting the importance of further clinical exploration. However, the Epic™ Max's engineered features make it an ideal choice for patients requiring bioprosthetic aortic valve replacement, offering potential benefits in surgical contexts today and into the future.

The Epic Plus Mitral and Aortic Stented Tissue Valves from Abbott represent the latest generation of the Epic Platform, designed for patients requiring heart valve replacement due to diseased, damaged, or malfunctioning valves. These bioprosthetic valves are engineered with advanced features aimed at enhancing radiopacity and implantability, facilitating interventions for patients with challenging anatomies. The mitral variant boasts low stent post height and unique leaflet design to prevent left ventricular outflow tract obstruction, while the aortic version is equipped to withstand high pressures during procedures like balloon valvuloplasty. Both valves incorporate Linx anticalcification treatment, potentially improving long-term valve performance and durability, though clinical validation is ongoing. The platform's design considers future-forward solutions such as supra-annular implantation and mitigation of post-implant complications, ensuring compatibility with transcatheter aortic valve replacement procedures.

The MitraClip™ G5 Transcatheter Edge-to-Edge Repair (TEER) system by Abbott is a sophisticated solution for treating mitral valve regurgitation (MR). It is particularly indicated for patients with symptomatic primary or secondary MR, classified as significant. The G5 system is an evolution of Abbott's TEER technology, designed to enhance procedural control and efficiency. Features include easy handling, precise positioning, and intuitive deployment, owing to its advanced attachment mechanisms and securement features that simplify connection and disconnection procedures. The system offers different clip sizes—NTW, XTW, NT, and XT—allowing for tailored repairs based on an individual patient's mitral valve anatomy. The wider grasping area of the NTW and XTW clips aims to further reduce regurgitant volume effectively. The system incorporates controlled gripper actuation, offering simultaneous or independent leaflet grasp, which helps confirm and optimize leaflet stabilization. Proven in clinical studies, the MitraClip system delivers consistent MR reduction and improved patient quality of life.

The TriClip™ Transcatheter Tricuspid Valve Repair System, developed by Abbott, is specifically designed for the minimally invasive treatment of severe tricuspid regurgitation (TR), particularly in patients who face high surgical risks. This device provides a transcatheter edge-to-edge repair (TEER) approach, leveraging proven leaflet repair technology to achieve consistent reduction in TR. It offers stable navigation and precise delivery, supported by an intuitive design that simplifies handling and deployment. The system includes innovative components such as a delivery catheter handle, arm positioner, and a guide attachment braking system, all engineered to enhance safety and efficacy. It is distinct in its focus on the tricuspid valve, providing a critical, less-invasive alternative for improving patients' quality of life and reducing heart failure hospitalizations when compared to traditional medical therapy. The system is available in multiple implant sizes to cater to patient-specific anatomical needs.